See more : Becle, S.A.B. de C.V. (CUERVO.MX) Income Statement Analysis – Financial Results
Complete financial analysis of Eterna Therapeutics Inc. (BTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eterna Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Argo Global Listed Infrastructure Limited (ALI.AX) Income Statement Analysis – Financial Results
- Seya Industries Limited (SEYAIND.BO) Income Statement Analysis – Financial Results
- YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF) Income Statement Analysis – Financial Results
- Seven & i Holdings Co., Ltd. (3382.T) Income Statement Analysis – Financial Results
- Go Fashion (India) Limited (GOCOLORS.NS) Income Statement Analysis – Financial Results
Eterna Therapeutics Inc. (BTX)
About Eterna Therapeutics Inc.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68.00K | 0.00 | 0.00 | 0.00 | 19.81M | 23.34M | 21.27M | 22.31M | 24.52M |
| Cost of Revenue | 236.00K | 497.00K | 459.00K | 98.00K | 7.84M | 8.39M | 7.09M | 8.13M | 13.06M |
| Gross Profit | -168.00K | -497.00K | -459.00K | -98.00K | 11.96M | 14.95M | 14.19M | 14.18M | 11.46M |
| Gross Profit Ratio | -247.06% | 0.00% | 0.00% | 0.00% | 60.40% | 64.07% | 66.68% | 63.55% | 46.74% |
| Research & Development | 5.92M | 10.39M | 12.71M | 3.95M | 26.00K | 72.00K | 139.00K | 0.00 | 0.00 |
| General & Administrative | 14.59M | 16.84M | 14.72M | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.59M | 16.84M | 14.72M | 3.30M | 13.15M | 14.41M | 15.45M | 16.46M | 18.06M |
| Other Expenses | 461.00K | -1.17M | 899.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 20.73M | 27.23M | 27.43M | 7.25M | 13.18M | 14.49M | 15.59M | 16.46M | 18.06M |
| Cost & Expenses | 21.20M | 27.23M | 27.43M | 7.25M | 21.02M | 22.87M | 22.68M | 24.59M | 31.12M |
| Interest Income | 138.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K |
| Interest Expense | 614.00K | 30.00K | 74.00K | 43.00K | 249.00K | 389.00K | 498.00K | 576.00K | 484.00K |
| Depreciation & Amortization | 1.12M | 497.00K | 459.00K | 98.00K | 3.17M | 2.76M | 2.32M | 2.89M | 3.10M |
| EBITDA | -19.93M | -33.22M | -121.95M | -7.15M | 1.96M | 3.23M | 915.00K | 609.00K | -3.63M |
| EBITDA Ratio | -29,314.71% | 0.00% | 0.00% | 0.00% | 9.88% | 13.83% | 4.30% | 2.73% | -14.26% |
| Operating Income | -21.14M | -33.22M | 68.34M | -7.25M | -1.21M | 464.00K | -1.40M | -2.28M | -6.60M |
| Operating Income Ratio | -31,080.88% | 0.00% | 0.00% | 0.00% | -6.12% | 1.99% | -6.59% | -10.21% | -26.92% |
| Total Other Income/Expenses | -536.00K | 8.68M | -95.05M | -19.28M | -808.00K | -787.00K | 391.00K | -607.00K | -614.00K |
| Income Before Tax | -21.67M | -24.53M | -122.30M | -7.29M | -2.02M | -323.00K | -1.01M | -2.89M | -7.21M |
| Income Before Tax Ratio | -31,869.12% | 0.00% | 0.00% | 0.00% | -10.20% | -1.38% | -4.75% | -12.93% | -29.42% |
| Income Tax Expense | -3.00K | 45.00K | 5.00K | -19.20M | 27.00K | -64.00K | 66.00K | 38.00K | 12.00K |
| Net Income | -21.67M | -24.58M | -122.31M | 11.91M | -2.05M | -259.00K | -1.08M | -2.92M | -7.23M |
| Net Income Ratio | -31,864.71% | 0.00% | 0.00% | 0.00% | -10.34% | -1.11% | -5.06% | -13.10% | -29.47% |
| EPS | -4.08 | -8.06 | -56.49 | 27.08 | -28.48 | -3.85 | -17.64 | -61.44 | -157.26 |
| EPS Diluted | -4.08 | -8.06 | -56.49 | 27.08 | -28.48 | -3.85 | -17.64 | -61.44 | -157.26 |
| Weighted Avg Shares Out | 5.31M | 3.05M | 2.17M | 439.70K | 71.88K | 67.20K | 61.05K | 47.58K | 45.95K |
| Weighted Avg Shares Out (Dil) | 5.31M | 3.05M | 2.17M | 439.70K | 71.88K | 67.20K | 61.05K | 47.58K | 45.95K |
Brooklyn Immuno Reports Inducement Grants
BROOKLYN, N.Y., July 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic...
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer
NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic...
Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood...
7 Top-Rated Pharmaceutical Companies to Invest In for July
Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In for July appeared first on InvestorPlace.
Brooklyn ImmunoTherapeutics Reports Inducement Grants
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood...
7 Best Reddit Stocks to Buy If You Have $100 to Spare
Looking to roll the dice? Consider buying one (or more) of these seven high-risk, but possibly high-return, Reddit stocks.
Why Brooklyn ImmunoTherapeutics Crushed the Market Today
The biotech is bulking up with a new acquisition.
Brooklyn ImmunoTherapeutics Stock Rises After Novellus Therapeutics Buyout Deal
Brooklyn ImmunoTherapeutics LLC (NYSE: BTX) has executed a non-binding letter of intent to acquire Novellus Therapeutics, a company developing engineered mesenchymal stem cell (MSC) therapies using mRNA cell reprogramming and gene editing technologies licensed from Factor Bioscience. Under the terms of the LOI, the...
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics
Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologies Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologies
Source: https://incomestatements.info
Category: Stock Reports